1403783-31-2

Basic information

• Product Name: Nexturastat A
• Synonyms: Nexturastat A;Benzamide, 4-[[butyl[(phenylamino)carbonyl]amino]methyl]-N-hydroxy-;Nexturastat A 4-((1-BUTYL-3-PHENYLUREIDO)METHYL)-N-HYDROXYBENZAMIDE;Nexturastat A Benzamide, 4-[[butyl[(phenylamino)carbonyl]amino]methyl]-N-hydroxy-;Nexturastat A, >=98%;4-[[Butyl[(phenylamino)carbonyl]amino]methyl]-N-hydroxybenzamide
• CAS NO: 1403783-31-2
• Molecular Formula: C₁₉H₂₃N₃O₃
• Molecular Weight: 341.40422
• Product Categories: Inhibitors
• Mol File: 1403783-31-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.228±0.06 g/cm3(Predicted)
• Solubility: insoluble in H2O; ≥16.3 mg/mL in DMSO; ≥9.3 mg/mL in EtOH
• PKA: 8.95±0.10(Predicted)
• CAS DataBase Reference: Nexturastat A(CAS DataBase Reference)
• NIST Chemistry Reference: Nexturastat A(1403783-31-2)
• EPA Substance Registry System: Nexturastat A(1403783-31-2)

Safety Data

• Hazardous Substances Data: 1403783-31-2(Hazardous Substances Data)

Usage

Uses

Nexturastat A is a potent and selective histone deacetylase 6 (HDAC6) inhibitor that shows potential antiproliferative effects against melanoma cells.

Biological Activity

nexturastat a is a selective inhibitor of histone deacetylase 6 (hdac6) with ic50 value of 5.2 nm [1].nexturastat a is a hdac inhibitor. it was developed by structural modification of aryl urea hdacis. the inhibitory activity of nexturastat a is most potent against hdac6 with ic50 value of 5.2 nm. besides that, nexturastat a also shows inhibition of other hdacs with ic50 values of 3.02, 6.92, 6.68, 9.39, 11.7, 4.46, 0.954, 6.72, 7.57 and 5.14 μm for hdac1, 2, 3, 4, 5, 7, 8, 9, 10 and 11, respectively. nexturastat a has been shown to suppress cell proliferation and promote apoptosis in b16 murine melanoma cells [1, 2].

references

[1] kalin j h, bergman j a. development and therapeutic implications of selective histone deacetylase 6 inhibitors. journal of medicinal chemistry, 2013, 56(16): 6297-6313.[2] zhang l, han y, jiang q, et al. trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy. medicinal research reviews, 2014.

Upstream product

• 1403690-26-5 methyl 4-((1-butyl-3-phenylureido)methyl)benzoate 
• 1019544-14-9 methyl 4-((butylamino)methyl)benzoate 
• 1571-08-0 methyl 4-formylbenzoate 

Relevant articles and documents

SELECTIVE HISTONE DEACTYLASE 6 INHIBITORS

Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Specifically, the disclosed subject matter relates to compounds having activity as selective HDAC6 inhibitors, methods of making and using the compounds, and compositions comprising the compounds. In still further aspects, the disclosed subject matter relates to methods for treating oncological disorders in a patient. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.

Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth

The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies. In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor. Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compounds bearing a branched linker group results in increased potency and selectivity for HDAC6. Compound 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of ～600-fold relative to the inhibition of HDAC1. These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth. To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.